Record Quarterly Revenue
BrainsWay reported record quarterly revenue of $13.5 million for Q3 2025, a 29% increase compared to the same period last year.
Increase in Deep TMS System Shipments
The company shipped 90 Deep TMS systems during the quarter, a 43% increase compared to the same period last year, bringing the total installed base to over 1,600 systems globally.
Raised Financial Guidance
BrainsWay raised the midpoint of their full-year 2025 revenue guidance to $51-52 million, up from $50-52 million, and increased expected operating profit to 6-7% of revenue from 4-5%.
FDA Approval for Accelerated Protocol
The U.S. FDA granted an expansion of the treatment protocol for the Deep TMS system to include an accelerated protocol for major depressive disorder, potentially improving patient convenience and appeal.
Strategic Investments and Growth
BrainsWay made strategic minority investments in mental health providers, with utilization of Deep TMS systems at partner clinics increasing over 50% since collaboration.
Strong Financial Performance
Q3 2025 gross profit was $10.2 million, with a strong gross margin of 75%. Net profit increased to $1.6 million from $0.7 million in Q3 2024.